Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Myeloperoxidase: A new player in autoimmunity. Cell Immunol 2017 Jul;317:1-8

Date

05/18/2017

Pubmed ID

28511921

Pubmed Central ID

PMC5665680

DOI

10.1016/j.cellimm.2017.05.002

Scopus ID

2-s2.0-85018938226   52 Citations

Abstract

Myeloperoxidase (MPO) is the most toxic enzyme found in the azurophilic granules of neutrophils. MPO utilizes H2O2 to generate hypochlorous acid (HClO) and other reactive moieties, which kill pathogens during infections. In contrast, in the setting of sterile inflammation, MPO and MPO-derived oxidants are thought to be pathogenic, promoting inflammation and causing tissue damage. In contrast, evidence also exists that MPO can limit the extent of immune responses. Elevated MPO levels and activity are observed in a number of autoimmune diseases including in the central nervous system (CNS) of multiple sclerosis (MS) and the joints of rheumatoid arthritis (RA) patients. A pathogenic role for MPO in driving autoimmune inflammation was demonstrated using mouse models. Mechanisms whereby MPO is thought to contribute to disease pathogenesis include tuning of adaptive immune responses and/or the induction of vascular permeability.

Author List

Strzepa A, Pritchard KA, Dittel BN

Author

Kirkwood A. Pritchard PhD Professor in the Surgery department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Animals
Autoimmune Diseases
Autoimmunity
Capillary Permeability
Dendritic Cells
Humans
Inflammation
Mice
Molecular Targeted Therapy
Peroxidase
jenkins-FCD Prod-482 91ad8a360b6da540234915ea01ff80e38bfdb40a